Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseNMR Meets Tau: Insights into Its Function and PathologyIntrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau FragmentationIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesStructural determinants of Tau aggregation inhibitor potencyPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesMethylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicityRole of the Keap1/Nrf2 pathway in neurodegenerative diseases.Structure and mechanism of action of tau aggregation inhibitors.FRET-based calcium imaging: a tool for high-throughput/content phenotypic drug screening in Alzheimer disease.PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies.Targeting intrinsically disordered proteins in rational drug discovery.Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer.What Renders TAU ToxicAttenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.Potential synergy between tau aggregation inhibitors and tau chaperone modulators.Cellular factors modulating the mechanism of tau protein aggregation.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's DiseaseAlternative conformations of the Tau repeat domain in complex with an engineered binding protein.Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.An ATR-FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and Aβ.The Molecular Chaperone Artemin Efficiently Blocks Fibrillization of TAU Protein In Vitro.Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases.Photoexcited Porphyrins as a Strong Suppressor of β-Amyloid Aggregation and Synaptic Toxicity.Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.
P2860
Q26739412-C2577132-183D-4A9A-BB85-A3BF0753F8CEQ26747418-3FCBA6C7-4EB6-4FD2-8B56-62C722C8B114Q28552366-66D16FA5-2DBB-4297-848A-C97EA661EF9FQ28597211-010689C0-2B1B-443C-BBCB-61A347D27D99Q30353954-84E8243D-F4D8-4729-AD16-261AFF7E0D58Q30649677-23DF0B5C-4CDA-4108-9905-E222F69355E1Q30669674-A6DF3859-7963-4FFE-A530-3DEDB15FAD3DQ33784466-ECDB7F31-C7E7-4364-AB14-E162F98F1691Q34464138-8B6CF981-FB03-4397-A52D-4D443B8E0912Q34902096-E36BDC4E-89DF-4D57-99BD-23C68003028BQ35039801-AD0DC3FC-5312-4D11-BBEA-479DE9C87253Q35058484-A17570D8-33B7-4E15-80AD-FE44B5328C60Q35669674-8657BFAA-DE78-4A34-A92F-E771E2CE2C4FQ35835558-2F49D8A0-6009-4694-BF90-35AC47F51710Q36818806-4EAD253E-B378-40AF-AA63-DF5D07724F7FQ36914658-7A24ECBB-8949-4A10-894E-B4CE36E2E4B0Q37314665-90835D5F-6AB4-4AB0-83DA-69E37EDDA4C2Q37417421-372BD087-6678-4621-956F-B266CAB1A9C5Q37695237-ACA1A834-8B29-443A-AF15-6FFE78739F5FQ38138165-D9D7298C-F063-4B67-914D-35EC99E54BCAQ38350075-3DF54470-80B3-41E1-B1B4-83DFAEF33D54Q38715233-29B38C67-37E8-4F20-9EE1-5A6D462994A8Q38833034-EE3DF650-AC33-4492-8732-5F3FD9CD1A30Q38901388-25CF16E9-6CE1-4287-8D79-CFD34467A41AQ38983187-D0DA51E4-E317-49CD-A51F-931ECCA534B7Q39035486-47BE5599-78A9-49F8-B38C-351197430561Q41786810-705C7D1C-885B-4F17-9CF0-BA94CC61504AQ42544519-309E09FB-94C1-410B-A0C9-4257C4315D84Q46784990-61ECE6F8-6087-4E57-9A9F-D518C27E12A3Q46800984-5361A7BE-7437-46C9-BBB6-8A9AF6834464Q47137171-DB96719F-87CB-4E53-A9EF-5B44042D9C4CQ47720283-35782100-C0DB-424C-B0F8-496013E36AFEQ50212166-02FAF027-ED04-4530-BC5A-4D7776CDCFE7Q52151823-E9594E0E-EB2E-43B7-8624-F37CF23D9062
P2860
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@en
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@nl
type
label
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@en
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@nl
prefLabel
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@en
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@nl
P2093
P2860
P50
P356
P1476
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
@en
P2093
Elias Akoury
Jacek Biernat
Marcus Pickhardt
P2860
P304
P356
10.1002/ANIE.201208290
P407
P577
2013-02-11T00:00:00Z